Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients.
about
STRUCTURE-FUNCTION OF THE TUMOR SUPPRESSOR BRCA1BRCAness: finding the Achilles heel in ovarian cancerCytotoxic and targeted therapy for hereditary cancersGenetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapyGermline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomasPhase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the TumorThe role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis.Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancerGermline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling.Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases.Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.Drug therapy for hereditary cancersA targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.In Vitro Enhanced Sensitivity to Cisplatin in D67Y BRCA1 RING Domain Protein.BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer.Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival.BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study.Are there candidates for high-dose chemotherapy in ovarian carcinoma?Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2Inhibition of BRCA2 and Thymidylate Synthase Creates Multidrug Sensitive Tumor Cells via the Induction of Combined "Complementary Lethality".Folic acid-targeted iron oxide nanoparticles as contrast agents for magnetic resonance imaging of human ovarian cancerSystemic treatment for hereditary cancers: a 2012 update.A chemotherapy response classifier based on support vector machines for high-grade serous ovarian carcinomaOvarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival.Translational genomics in cancer research: converting profiles into personalized cancer medicineOutcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.BRCA1 promoter hypermethylation in sporadic epithelial ovarian carcinoma: Association with low expression of BRCA1, improved survival and co-expression of DNA methyltransferases.Identification of Metabolic Biomarkers Using Serial 18F-FDG PET/CT for Prediction of Recurrence in Advanced Epithelial Ovarian CancerUse of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts.Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers.PARP inhibition and synthetic lethality in ovarian cancer.Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry.
P2860
Q24600363-F3DBF120-1432-4AD5-B88A-899E1ED280F0Q24630872-70770CBB-4F0B-4873-96ED-CB7052DF6343Q26739366-872E2941-5884-4E81-83BF-055E55983022Q26769604-8ED3AFEF-0FF0-446B-9BC1-9C7DCD8FB6B9Q27852671-FBC9A4D6-9CCD-4161-B732-2D314FC23D92Q33415400-9E47FBA8-1DE3-4DE5-B056-948588907F91Q33458308-B2952522-754E-4228-8B6E-94AF43D51650Q33553318-8303945F-109D-433E-AC69-655388268A69Q33704050-7D00722C-0B17-43D7-BD05-F8D144CB9685Q33735109-0F808B8F-7BA8-49A1-A91C-0571C6909CD4Q34305493-378A12C4-A0EC-4510-B99B-96565F0E867EQ34481713-8BDCEC53-5A35-4247-A4CC-36EB3900FC26Q34520145-4CE311F2-4EB1-4C41-A8AF-C49D6E46E67FQ34639149-186094AE-AE26-4EAB-A4F4-0F10465336C0Q34663583-0FBDF062-791C-4FA8-B14A-0BD9B930DA7EQ35208929-171521A2-0006-48BA-9877-39419F104679Q35223166-21C34601-8E64-4390-855C-17BE0DB01F09Q35440379-34CD7697-C29D-42B2-96F1-6EB354C10E21Q35674192-0ABB5D85-BDA1-424C-A29B-90C9B9B2613EQ35837949-B3178567-B5B1-4FDC-96EA-7550B29ECD78Q35914568-77E6D8AC-A777-4AC2-BD37-F8A1BB996ED8Q36145443-6579B0B3-94F7-4BB6-8588-B7609D3F0E35Q36171560-8914F57C-4CFE-429F-AF35-1B3327269DB7Q36468856-6DD8EAAA-2A53-4DCA-8075-7796C3DCAC3CQ36727459-B6016E8E-B0B1-472D-8A49-5F29A60AC3A2Q36738376-782BDE80-647D-4280-BD41-4018888DD6F6Q36742449-76E07BB0-DCAB-4EE4-8FB3-7C9F4A161E7EQ36755366-174B17F3-7C15-442B-B456-5BA3B3FF2A41Q36772106-2C1E6DF9-1D10-4780-A72A-55D1F6B075E1Q36983535-C2AC6B4F-DFDB-48D7-BF02-2740EF2B1C54Q37386249-D34EF31E-0357-46E3-9CB5-BFB5019F6B9BQ37408259-E3B4259C-4930-4F49-B6E1-5D7F3B08F686Q37470280-7A5A9BA1-D29F-42FA-A914-576C100B55F9Q37565541-468722EE-C397-4DFC-9DB3-489A0C61E199Q37652536-EC379AA6-D7A9-4879-9FE3-32FFF365C135Q37715868-DC65F51F-EB67-4DC9-9152-265290255E86Q37965631-8CF31B21-84CD-4A07-9FCC-337743AD135AQ38087850-EB5C2DA7-5FFD-42C1-A55A-81B219E29989Q38225315-DD205583-CC5C-4A7A-9CBD-C52E63E4581FQ38377713-E3511C31-4D14-4A9D-94C0-CCAA3B2FA5E2
P2860
Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Chemosensitivity and outcome o ...... radic ovarian cancer patients.
@en
Chemosensitivity and outcome o ...... radic ovarian cancer patients.
@nl
type
label
Chemosensitivity and outcome o ...... radic ovarian cancer patients.
@en
Chemosensitivity and outcome o ...... radic ovarian cancer patients.
@nl
prefLabel
Chemosensitivity and outcome o ...... radic ovarian cancer patients.
@en
Chemosensitivity and outcome o ...... radic ovarian cancer patients.
@nl
P2093
P2860
P921
P356
P1433
P1476
Chemosensitivity and outcome o ...... radic ovarian cancer patients.
@en
P2093
C W Burger
D Hoogwerf
M E L van der Burg
P M L H Vencken
S Beugelink
P2860
P304
P356
10.1093/ANNONC/MDQ628
P577
2011-01-12T00:00:00Z